Showing 1701-1710 of 7331 results for "".
Clinical Conversations: A conversation with Dr Angela Lamb, a dermatologist and professor in New York, New York
https://practicaldermatology.com/programs/nemluvio-peer-network/clinical-conversations-a-conversation-with-dr-angela-lamb-a-dermatologist-and-professor-in-new-york-new-york/37237/Dr Angela Lamb discusses her approach to treating prurigo nodularis (PN) and atopic dermatitis (AD). She’ll explain how NEMLUVIO®, the first and only neuroimmune-targeted therapy that blocks IL-31RA, targets both immune and neuronal pathways and addresses chronic itch, inflammation, and barrier disrTips and Tricks for Prescribing Biologics for Pediatric Patients
https://practicaldermatology.com/conferences/maui-derm-hawaii-2026/tips-and-tricks-for-prescribing-biologics-for-pediatric-patients/54662/Dawn Eichenfield, MD, PhD, discusses key takeaways from the “Pediatric Dermatology 2026” session at Maui Derm Hawaii 2026.Targeting Senescent Cells
https://practicaldermatology.com/series/c-suite-chats/targeting-senescent-cells/35960/Rubedo Life Science CEO Frederick Beddingfield III, MD, PhD, FAAD, FACMS, talks about the importance of addressing aging and senescence, and his company's investigational drug that targets pathological senescent cells and surrounding tissues that drive inflammaging and chronic degenerative diseasesPractical Dermatology Roundtable: Generalized Pustular Psoriasis, Ch. 2
https://practicaldermatology.com/programs/practical-dermatology/practical-dermatology-roundtable-generalized-pustular-psoriasis-ch-2/32758/Host Neal Bhatia, MD, FAAD, and guests Laura K. Ferris, MD, PhD, FAAD, and Jason E. Hawkes, MD, MS, FAAD, discuss the differences between psoriasis subtypes, the importance of a specialized therapeutic approach targeting the IL-36 pathway for generalized pustular psoriasis, and the role of neutrophiPearls from CSF 2022
https://practicaldermatology.com/conferences/cosmetic-surgery-forum-2022/pearls-from-csf-2022/20163/It’s not just the attendees who learned at this year’s Cosmetic Surgery Forum. Meeting founder Joel Schlessinger, MD discusses some of the presentations that were most impactful to him. From presentations about the effectiveness of new technology to discussions about the usefulness of hyaluronidaseMaximizing Results: The Benefits of Biostimulators
https://practicaldermatology.com/conferences/asds-2022-annual-meeting/maximizing-results-the-benefits-of-biostimulators/20150/Patients often present with a desire for optimal results on a limited budget. Sabrina Fabi, MD shares how she effectively uses biostimulators in her practice. For low-volume, high-yield results, she recommends 1 vial every 8 months to a year. Alternating this with hyaluronic acid fillers, keeps everDERM2020 Content Recap: Linda Stein Gold, MD
https://practicaldermatology.com/conferences/dermatology-education-foundation-derm-2020/derm2020-content-recap-linda-stein-gold-md/19845/DERM2020 Faculty Linda Stein Gold, MD discusses what’s new in acne from her presentation during DERM2020.Dupixent, Juvéderm Vollure XC, Bavencio Approvals
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-dupixent-juv-derm-vollure-xc-bavencio-approvals/18698/The FDA has approved Regeneron's injectable Dupixent (dupilumab) to treat adults with moderate-to-severe eczema. It will be marketed by Regeneron and Sanofi Genzyme in the US. Allergan's Juvéderm Vollure XC has received FDA approval based on a pivotal clinical trial in which 59 percent of subjects sThe Menassaince
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/the-menassaince/18722/Men are an increasingly important demographic in aesthetics today, Steven Dayan, MD tells Dermtube host Joel Cohen, MD. Unlike their female counterparts, men tend to prefer one-and-done procedures and often seek treatment after hours, he says.ICD-10: When the Rubber Meets the Road
https://practicaldermatology.com/topics/practice-management/icd-10-when-the-rubber-meets-the-road/18632/When plans to move to ICD-10 were first announced, providers expressed concerns about potential logistical concerns with the new coding system. However, now that the new system is in regular use, Leon Kircik, MD said health claim denial rates have been lower than expected and the transition has been